Abstract
Estee Lauder will report its fiscal third-quarter results on May 01, 2026 Pre-Market; this preview summarizes consensus expectations for revenue, margins, net income, adjusted EPS, and key debates on product mix and regional trends for the upcoming quarter.
Market Forecast
Consensus for the current quarter points to revenue of 3.69 billion US dollars, up 4.84% year over year, with estimated EBIT of 417.29 million US dollars, an implied acceleration relative to last year’s comparable period, and estimated adjusted EPS of 0.65, up 103.56% year over year. The company’s prior report indicated sequential stabilization with gross profit margin at 76.50% and net profit margin at 3.83%; investors expect gross margin resilience near the mid-70s percentage range and net margin expansion as mix and overhead efficiency improve.
Management’s main business remains diversified across Skin Care, Makeup, Fragrance, and Hair Care; Skin Care is the core driver and the focus for recovery, while Fragrance continues to be a resilient category in prestige beauty and is watched for incremental growth. The segment with the clearest near-term potential is Skin Care at 2.05 billion US dollars last quarter; a mid-single-digit YoY recovery in core franchises and improving travel-retail sell-out are expected to lift performance, while Fragrance at 0.81 billion US dollars is viewed as a steady contributor.
Last Quarter Review
In the previous quarter, Estee Lauder reported revenue of 4.23 billion US dollars, gross profit margin of 76.50%, GAAP net profit attributable to the parent company of 162.00 million US dollars, net profit margin of 3.83%, and adjusted EPS of 0.89, with revenue up 5.62% year over year and adjusted EPS up 43.55% year over year.
A key highlight was profitability beating expectations, with EBIT of 608.00 million US dollars exceeding consensus and signaling early benefits from cost controls. The main business mix showed Skin Care at 2.05 billion US dollars, Makeup at 1.16 billion US dollars, Fragrance at 0.81 billion US dollars, Hair Care at 0.17 billion US dollars, and Others at 0.03 billion US dollars; Skin Care remained the largest contributor and the anchor for margin leverage.
Current Quarter Outlook
Main business: Prestige Skin Care and Makeup recovery path
The main business centers on Skin Care and Makeup, which together accounted for roughly three-quarters of last quarter’s revenue and define margin outcomes. For the current quarter, the central watchpoint is how restocking and sell-through normalize across channels, especially in travel retail and Asia wholesale. With consensus revenue growth at 4.84% and EPS up 103.56% year over year, the setup implies improving utilization of fixed costs and a healthier promotional posture versus last year’s reset, but still below pre-disruption growth velocities. Investors should focus on portfolio balance: hero franchises in Skin Care typically carry higher gross margins, which, if mix skews back toward these lines, can protect the mid-70s gross margin level even if volumes fluctuate. Makeup trends can support top line but are margin-dilutive relative to Skin Care; a prudent channel mix and controlled incentives will determine how much of the EPS inflection is kept.
Most promising business: Skin Care scale and innovation cadence
Skin Care, at 2.05 billion US dollars last quarter, remains the best positioned for comp improvement as innovation cycles, refillable formats, and hero line extensions improve price realization. Expectations into this print lean toward mid-single-digit sell-out improvement year over year, helped by progressive recovery in travel retail and steadier China domestic demand. The margin equation here is favorable: higher-priced serums and treatment products generally lift gross profit, so even moderate unit growth can yield noticeable EBIT leverage. The key sensitivity is inventory and channel health; if retailer inventories stay lean and reorder rates firm, working capital should improve along with margins, amplifying the EPS flow-through. A positive surprise would combine improving organic sell-out with early signs of mix-led gross margin uplift.
Stock-price drivers: Travel retail, China normalization, and cost discipline
Three variables are likely to drive the stock this quarter. Travel retail trends, especially in Asia travel corridors, need to show sequential improvement in both traffic and conversion after last year’s reset; stabilization here can support Skin Care volumes and reduce the need for promotions. China normalization remains pivotal for category momentum and channel rebalancing; a steady consumer backdrop and balanced wholesale shipments would support the 4.84% revenue growth assumption and EPS recovery. Cost discipline will bridge the model, as last quarter’s 608.00 million US dollars in EBIT outpaced estimates; the market expects continued operating efficiency to sustain a net margin expansion from the 3.83% baseline. Any shortfall in these three areas would pressure the EPS estimate of 0.65 and cap multiple expansion.
Analyst Opinions
Across recent institutional commentary, the majority stance skews neutral-to-cautious rather than outright bullish. Several firms maintained Hold ratings with price targets in the 80–130 US dollars range, reflecting a preference to see a firmer cadence of revenue growth and confirmation of sustained margin improvement. UBS, TD Cowen, Canaccord Genuity, Jefferies, and Berenberg maintained Hold views, while Goldman Sachs reiterated a Buy, creating a mix that leans toward neutrality with a cautious tilt.
The center of the debate is whether the recovery in travel retail and Asia is sufficiently advanced to drive durable mid- to high-single-digit revenue growth and whether Skin Care mix can re-accelerate without elevating promotions. Hold-leaning analysts point out that while last quarter delivered a solid EBIT beat and 43.55% adjusted EPS growth, the net margin at 3.83% still indicates early-stage recovery with execution risk in channel rebalancing. Supportive analysts highlight improving operational efficiency and the potential for inventory normalization to allow stronger gross margin capture, citing consensus EBIT of 417.29 million US dollars and the sharp year-over-year EPS growth estimate as evidence of progress.
The prevailing view expects a constructive but measured quarter: if revenue lands near 3.69 billion US dollars with disciplined channel mix and gross margin resilience in the mid-70s percentage range, upside to EPS is possible. However, most institutions prefer confirmation on travel retail sell-through and China consumption trends before turning decisively positive. Within this context, we assess the majority tone as neutral-to-cautious, emphasizing execution on mix and cost controls as the critical swing factors for the print on May 01, 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments